Pulmatrix EPS - Earnings per Share 2014-2022 | PULM
Pulmatrix eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Pulmatrix Annual EPS |
2021 |
$-8.63 |
2020 |
$-13.43 |
2019 |
$-24.60 |
2018 |
$-99.60 |
2017 |
$-186.40 |
2016 |
$-376.00 |
2015 |
$-646.00 |
2014 |
$-6,904.00 |
2014 |
$-765.00 |
2013 |
$0.00 |
2013 |
$-130.00 |
2012 |
$-130.00 |
Pulmatrix Quarterly EPS |
2022-03-31 |
$-1.51 |
2021-12-31 |
$-2.45 |
2021-09-30 |
$-3.00 |
2021-06-30 |
$-1.40 |
2021-03-31 |
$-1.78 |
2020-12-31 |
$-1.63 |
2020-09-30 |
$-6.20 |
2020-06-30 |
$-1.00 |
2020-03-31 |
$-4.60 |
2019-12-31 |
$2.00 |
2019-09-30 |
$-3.60 |
2019-06-30 |
$-8.20 |
2019-03-31 |
$-14.80 |
2018-12-31 |
$-4.40 |
2018-09-30 |
$-20.60 |
2018-06-30 |
$-26.80 |
2018-03-31 |
$-47.80 |
2017-12-31 |
$-42.40 |
2017-09-30 |
$-44.00 |
2017-06-30 |
$-58.00 |
2017-03-31 |
$-42.00 |
2016-12-31 |
$-134.00 |
2016-09-30 |
$-42.00 |
2016-06-30 |
$-124.00 |
2016-03-31 |
$-76.00 |
2015-12-31 |
$2,486.00 |
2015-09-30 |
$-68.00 |
2015-06-30 |
$-1,154.00 |
2015-03-31 |
$-1,910.00 |
2014-12-31 |
$-175.00 |
2014-09-30 |
$-11,920.00 |
2014-06-30 |
$-442.00 |
2014-03-31 |
$-230.00 |
2013-12-31 |
$-165.00 |
2013-09-30 |
$-250.00 |
2013-06-30 |
$-120.00 |
2013-03-31 |
$-115.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.017B |
$0.005B |
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|